CardioExchange Archive

March 10th, 2013

Eplerenone May Help Prevent Heart Failure in Acute STEMI Patients

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. A new trial presented at the ACC in San Francisco suggests that the mineralocorticoid-receptor antagonist eplerenone (Pfizer, Inspra) may […]

---

August 30th, 2011

New Results from EMPHASIS-HF Show Big Benefits For High-Risk Subgroups Taking Eplerenone

Larry Husten, PHD

Last November the main results of the EMPHASIS-HF trial demonstrated that eplerenone was significantly better than placebo in reducing the risk for death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial, presented by Bertram Pitt at the European Society of Cardiology meeting in Paris, reinforces the earlier findings […]

---

May 23rd, 2011

Eplerenone Found to Also Reduce AF in Heart Failure Patients

Larry Husten, PHD

Results from EMPHASIS-HF (Eplerenone and Atrial Fibrillation in Patients with Systolic Heart Failure and Mild Symptoms) previously showed that adding the aldosterone antagonist eplerenone to standard therapy in patients with NYHA class II heart failure resulted in the reduction of the composite endpoint of death from cardiovascular causes or hospitalization for heart failure. Now, a […]

---

November 14th, 2010

Emphatic Support for Eplerenone in NYHA Class II Heart Failure

Larry Husten, PHD

Aldosterone antagonists have proven beneficial in heart failure patients with moderate-to-severe symptoms and in MI patients with LV dysfunction and heart failure. Now EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) has extended these benefits to patients with systolic HF and mild symptoms. EMPHASIS HF randomized 2737 patients with NYHA class II […]

---